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a b s t r a c t
An accurate assessment of kidney function before hematopoietic cell transplantation (HCT) can help to
properly dose conditioning chemotherapy and follow patients for the development of chronic kidney disease.
We cross-sectionally examined 94 children and young adults before HCT to compare formal nuclear
glomerular ﬁltration rate (GFR) testing with estimated GFR using creatinine and cystatin Cebased equations,
including the original Schwartz formula and the more recent formulas developed in the Chronic Kidney
Disease in Children (CKiD) cohort. The median age of the cohort was 5.9 years (range, .26 to 30.5 years). The
mean cohort nuclear GFR was 107.4  24.7 mL/min/1.73 m2, with 18 of 94 subjects (19.1%) having abnormal
kidney function (GFR < 90 mL/min/1.73 m2) before HCT. The creatinine-based original Schwartz and bedside
CKiD formulas showed signiﬁcant bias, overestimating the nuclear GFR by 57.4 (95% conﬁdence interval [CI],
49.0 to 65.8) and 14.1 (95% CI, 7.1 to 21.1) mL/min/1.73 m2, respectively. Cystatin C formulas had less mean
bias and improved accuracy but also had decreased sensitivity to detect abnormal kidney function before HCT.
The Full CKiD equation showed the best performance, with a mean bias of 3.6 mL/min/1.73 m2 (95% CI, 8.4
to 1.2) that was not signiﬁcantly different from the measured value and 87.7% of estimates within 30% of the
nuclear GFR. Although the more recent bedside CKiD formula performed better than the original Schwartz
formula, both formulas had poor sensitivity for detecting a low GFR. An abnormal pretransplant nuclear GFR
was not associated with post-HCT acute kidney injury, the need for dialysis, or death in the ﬁrst 100 days. In
conclusion, we observed cystatin Cebased equations outperformed creatinine-based equations in estimating
GFR in children before HCT. However, all formulas had decreased sensitivity to detect impaired GFR. Formal
measurement of kidney function should be considered in children and young adults who need an accurate
assessment of kidney function before HCT.
 2014 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Chronic kidney disease (CKD) occurs in at least 15% of
patients after hematopoietic cell transplantation (HCT) [1].
Certain chemotherapeutic agents used for conditioning
before HCT need to be dose-adjusted depending on the
glomerular ﬁltration rate (GFR) [2]. After transplantation, an
accurate assessment of GFR is needed to dose other
medications, including antibiotics and calcineurin inhibitor
therapy for graft-versus-host disease (GVHD) prophylaxis,
and to monitor patients over time for the development of
CKD [3].
Outside of research protocols, there are no established
guidelines for how to assess kidney function (GFR) before
HCT. Available options include serum creatinine, 24-hour
urine collections for creatinine clearance, and formal
measurements of GFR using an injected nuclear isotope or
contrast agent such as iohexol. Some have suggested that a
pre-HCT serum creatinine  1.5 mg/dL and a creatinine
clearance >60 mL/min are preferred before starting
transplant [4]. Although creatinine may have a limited
ability to estimate GFR in patients with low muscle mass,
formal GFR testing is more costly, invasive, and time
consuming [3,5].
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We reported that cystatin C was more accurate than
creatinine in estimating GFR in 16 children receiving autol-
ogous HCT [6]. Unlike serum creatinine, cystatin C may be
independent of muscle mass but possibly affected by other
nonrenal factors such as corticosteroid treatment or body
weight [5,7]. Cystatin C has been less studied in patients
undergoing HCT [8-12]. Our objective was to expand on our
prior work by examining GFR in a larger cohort of children
and young adults before HCT, which included allogeneic re-
cipients. We used the most recent estimating equations
recommended by the 2012 Kidney Disease Improving Global
Outcomes consensus guidelines [13] and focused on
comparing creatinine-estimated GFR to a measured nuclear
GFR and secondarily included cystatin Ceestimated GFR.
METHODS
Study Population
We conducted a cross-sectional analysis of children and young adults
who were enrolled in a prospective cohort originally designed to study risk
factors for thrombotic microangiopathy after HCT. The cohort included 100
consecutive children and young adults receiving an HCT at Cincinnati Chil-
dren’s Hospital Medical Center (CCHMC) from September 2010 to December
2011. Of these 100 subjects, 95 had a nuclear GFR performed for clinical
indications before transplant. Two autologous recipients were reported in
our previous study [6]. Clinical data were recorded from the medical record
and included age, gender, primary diagnosis, race, height, weight, exposure
to prior chemotherapy, number of prior HCTs (if any), corticosteroid therapy
before transplant, and creatinine and blood urea nitrogen values. We also
captured outcome data, including the development of acute kidney injury
(AKI, deﬁned as a doubling of each subject’s baseline serum creatinine), the
need for dialysis, or death within the ﬁrst 100 days after HCT. Cystatin C was
measured on prospectively collected and stored plasma samples, as
described below.
We included subjects with a creatinine and/or cystatin C measurement
within 3 days of nuclear GFR testing. For subjects withmore than a 3-day lag
between the measured creatinine and/or cystatin Ceestimated GFRs, we
only included subjects who were not admitted to the hospital and had not
received nephrotoxic antibiotics between testing. In addition, for analyses
incorporating cystatin C, we excluded subjects with cystatin C testing per-
formed after the start of conditioning and also those with unstable kidney
function (deﬁned as an intrasubject creatinine standard deviation .1, as
reported previously [6]) between cystatin C and nuclear GFR testing. The
research was approved by the Institutional Review Board at CCHMC.
Measurement of GFR
GFR was measured using 99mTc-labeled diethylene triamine pentaacetic
acid (DTPA). The procedure was performed and clearance calculated as pre-
viously described [6,14]. In brief, after a single injection of DTPA, plasma
samples were obtained at approximately 120, 150, 180, and 210 minutes. GFR
was calculatedusing a slope-intercept, orone compartment,methodbasedon
the terminal portion of the plasma clearance curve. A quadratic correction
factor was then used to adjust the slope-intercept GFR to a 2-compartment
model using the methods of Brochner-Mortensen with coefﬁcients that
were recently validated in children by Schwartz et al. [3] (GFR
corrected ¼ .995  GFR measured e .001159) (GFR measured2).
Estimation of GFR
Primary analysis: creatinine-estimated GFR versus measured nuclear GFR
Our primary objective was to compare serum creatinine-estimated GFR
with each subject’s measured nuclear GFR. Serum creatinine values were
obtained clinically and measured with an enzymatic assay (Ortho Vitros
Fusion, Rochester, NY) in the CCHMC clinical laboratory. In subjects with
more than 1 measurement, we examined the serum creatinine value closest
to the date the nuclear GFR was performed. In the entire cohort, GFR was
separately estimated with the original Schwartz formula [15] and the new
“bedside” Chronic Kidney Disease in Children (CKiD) formula [16]. For
subjects 18 years of age, we also estimated GFR using the Modiﬁcation of
Diet in Renal Disease (MDRD) formula [17] and the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) creatinine-only formula [18]. The
GFR estimating equations are shown in Table 1.
Secondary analysis: cystatin Ceestimated GFR versus measured nuclear GFR
Weincludedcomparisons using cystatinCeestimatedGFRas a secondary
analysis because there was a lag between cystatin C testing and the nuclear
GFR measurement in some subjects (see below). Plasma was collected from
each subject before HCT and stored at 80C before cystatin C testing. Cys-
tatin C concentrations were measured in the CCHMC Division of Nephrology
clinical laboratory using particle-enhanced immunonephelometry (Siemens
Healthcare Diagnostics Products, Erlangen, Germany). To compare the per-
formance of cystatin C and creatinine-estimated GFR with the nuclear GFR,
we used the creatinine measure closest in time to the cystatin C result. In the
entire cohort, GFR was separately estimated with the CKiD cystatin Ceonly
formula and the Full CKiD formula combining cystatin C, creatinine, and
blood urea nitrogen [7]. For subjects18 years of age, we also estimated GFR
using the CKD-EPI cystatin Ceonly and the CKD-EPI combined creatinine and
cystatin C formulas (Table 1) [19].
Statistical Analyses
Descriptive statistics for continuous variables were reported as medians
and interquartile ranges (IQR) or number of case and percentages for cate-
gorical variables. The GFR values were reported as means and standard de-
viations. To compare the estimating equations to nuclear GFR estimation,
mean bias and 95% limits of agreement were calculated according to the
methods of Bland and Altman [20]. We also computed each equation’s ac-
curacy as the proportion of the estimated GFR values within10% and30%
of the gold standard, which are accepted criteria for evaluating equation
performance [13]. In addition, we calculated the sensitivity and speciﬁcity of
each equation to detect a decreased nuclear GFR (ie, abnormal kidney func-
tion), deﬁned as<90mL/min/1.73m2 in those2 years old [13]. For children
<2 years old, we used published age-based normal values [21] to deﬁne
abnormal kidney function as <2 standard deviations below the mean. We
also examined a GFR cutoff of <50 to 60 mL/min/1.73 m2 because this
threshold is used for dosing adjustment of medications used in HCT condi-
tioning, including ﬂudarabine, melphalan, platinum drugs, etoposide, car-
mustine, and cytarabine [22,23]. Finally, we examined the association
between a decreased pretransplant nuclear GFR and post-HCT renal out-
comes (deﬁned separately asAKI, dialysis, or death in theﬁrst 100days) using
univariate logistic regression.
Estimating equation performance was examined in the cohort as a
whole and separately using pediatric and adult-speciﬁc formulas in those
<2 and 18 years of age. Analyses were conducted using SAS (version 9.3,
SAS Institute, Cary, NC) and STATA software (version 12, College Station, TX).





Original Schwartz k  height (cm)/SCr, where k is .7 for males
13-18 yr of age, .45 for children <1 yr of age,
and .55 otherwise.
Bedside CKiD .413  height (cm)/SCr
Cystatin Cebased formula
CKiDcys 70.69  (cys)e.931
Combined cystatin C and creatinine formula
Full CKiD 39.1 (height (m)/SCr).516  (1.8/cys).294
 (30/BUN).169  (1.099)male  (height
(m)/1.4).188
Age  18 yr
Creatinine-based formulas
MDRD 175  SCr1.154  agee.203  .742
(if female)  1.212 (if African American)
CKID-EPIcreat 141  (minimum of SCr/k or 1)a  (maximum
of SCr/k or 1)1.209  .993age  1.018
(if female)  1.159 (if black), where k is .7 for
females and .9 for males and a is e.329 for
females and e.411 for males.
Cystatin Cebased formula
CKD-EPIcys 133  (minimum of cys/.8 or 1)e.499 
(maximum of cys/.8 or 1)1.328 
.996age  .932 (if female)
Combined cystatin C and creatinine formula
CKD-EPIcreat-cys 135  (minimum of SCr/k or 1)a  (maximum of
SCr/k or 1)e.601  (minimum of cys/
.8 or 1)e.375  (maximum of cys/.8 or 1)e.711
.995age  .969 (if female)  1.08 (if black),
where k is .7 for females and .9 for males and a
is e.248 for females and e.207 for males.
cm indicates centimeters; SCr, serum creatinine (mg/dL); cys, cystatin C
(mg/L); m, meters; BUN, blood urea nitrogen (mg/dL).
GFR in mL/min/1.73 m2.
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RESULTS
Subjects
For the primary analysis, 77 of 95 subjects (81.1%) had a
creatinine value obtained clinically within 3 days of nu-
clear GFR testing and were included. In the remaining 18
subjects, there was a median of 7 days (IQR, 5 to 13 days)
between the nuclear GFR and serum creatinine testing.
One of these 18 subjects was excluded because of admis-
sion for fever, leaving 94 subjects included in the primary
analysis. For the secondary analysis, we excluded subjects
as follows: 6 had their cystatin C obtained after the start of
conditioning, 7 had an intrasubject creatinine standard
deviation .1 between measures, and/or 10 were admitted
to the hospital between nuclear GFR and cystatin C testing.
This left a total of 73 subjects included in the secondary
analysis.
The clinical, demographic, and laboratory characteristics
of the included subjects are shown in Table 2. The median
age of the 94 subjects in the cohort was 5.9 years (IQR, 2.8 to
15.1 years), with the youngest subject age .26 years and the
oldest subject age 30.5 years. Most subjects (78/94, 83.0%)
were <18 years of age, with 19 of 94 subjects (20.2%)
<2 years of age. Most of the study population were male,
white, and diagnosed with a malignancy. Approximately 8%
of the subjects were receiving treatment with corticosteroids
at the time of cystatin C testing, about half had received prior
chemotherapy, and 3% had received a prior HCT.
Timing of the GFR Evaluations
The nuclear GFR was performed a median of 19 days (IQR,
13 to 32 days; range, 1 to 172 days) before the start of con-
ditioning chemotherapy. Cystatin C testing was performed
on frozen plasma samples collected a median of 2 days (IQR,
0 to 7 days) before the start of conditioning chemotherapy.
The serum creatinine and blood urea nitrogen values closest
to the cystatin C testing were obtained clinically a median of
0 days (IQR, 0 to 1 days; range, 0 to 15 days) from cystatin C
testing.
Performance of the GFR Estimating Equations
The mean cohort (N ¼ 94) nuclear GFR was
107.4  24.7 mL/min/1.73 m2. The mean GFR was
107.9  26.3 mL/min/1.73 m2 in the 78 subjects <18 years of
age, 104.5  14.5 mL/min/1.73 m2 in the 16 subjects
18 years of age, and 110.5  14.5 mL/min/1.73 m2 in the
subset of the 19 subjects <2 years of age. Using a cutoff of
<90mL/min/1.73m2 for those2 years of age and age-based
normative values for those < 2 years of age, 18 of 94 subjects
(19.1%) had abnormal kidney function before transplant.
Primary analysis: creatinine-estimated GFR versus the
nuclear GFR
Table 3 summarizes the performance of each estimating
equation in the entire cohort. The creatinine-based original
Schwartz and bedside CKiD formulas overestimated the nu-
clear GFR with a signiﬁcant mean bias of 57.4 (95% conﬁ-
dence interval [CI], 49.0 to 65.8) and 14.1 (95% CI, 7.1 to 21.1)
mL/min/1.73 m2, respectively. Although the mean bias of the
bedside CKiD formula was better than the original Schwartz
formula, its performance was not optimal because its accu-
racy was moderate, with 67.0% of the estimates within 30%
of the measured GFR.
The original Schwartz formula detected none of the 18
subjects with abnormal kidney function before transplant
Table 2
Clinical and Demographic Characteristics of the Study Cohort
Primary Analysis:
Creatinine vs. Nuclear
GFR (N ¼ 94)
Secondary Analysis:
Cystatin C vs. Nuclear
GFR (N ¼ 73)
Age, yr 5.9 (2.8-15.1) 6.7 (3.0-15.1)
Male gender 60 (63.8%) 44 (60.3%)
Primary disease
Malignancy 36 (38.3%) 31 (42.5%)
Immunodeﬁciency 32 (34.0%) 24 (32.9%)
Bone marrow failure 22 (23.4%) 15 (20.6%)
Genetic/metabolic 3 (3.2%) 2 (2.7%)
Benign hematological 1 (1.1%) 1 (1.4%)
Race
White 79 (84.0%) 63 (86.3%)
African American 12 (12.8%) 9 (12.3%)
Other 3 (3.2%) 1 (1.4%)
Height, cm 112.6 (87.0-156.6) 121.7 (91.2-158.4)
Weight, kg 22.7 (13.7-55.7) 24.9 (14.3-56.8)
Prior chemotherapy 46 (48.9%) 39 (53.4%)













Cystatin C, mg/L d .69 (.61-.78)
Steroid therapy
at time of cystatin C
d 6 (8.2%)
Values are median with IQR in parentheses or number of cases with per-
cents in parentheses.
Table 3
Performance of Pediatric GFR Estimating Equations in the Entire Cohort
Formula Mean GFR  SD Mean Bias (95% CI) 95% LOA 30% Accuracy* (%) 10% Accuracy* (%)
Primary analysis: creatinine formulas (N ¼ 94)
Nuclear GFR 107.4  24.7 d d d d
Original Schwartz 164.8  43.5y 57.4 (49.0-65.8) 22.7-137.5 22.3 9.6
Bedside CKiD 121.4  34.7y 14.1 (7.1-21.1) 53.0-81.1 67.0 29.8
Secondary analysis: cystatin C formulas (N ¼ 73)
Nuclear GFR 108.7  23.5 d d d d
CKiD cystatin C only 100.2  20.7y 8.6 (13.6 to 3.5) 51.0-33.8 87.7 41.1
Full CKiD 105.1  18.1 3.6 (8.4-1.2) 43.6-36.4 87.7 42.5
SD indicates standard deviation; LOA, limits of agreement.
GFR in mL/min/1.73 m2.
* 30% accuracy is the percentage of estimated GFR values falling within 30% of the nuclear GFR, and 10% accuracy is the percentage of estimated GFR values
falling within 10% of the nuclear GFR.
y Signiﬁcantly different from nuclear GFR (P < .05).
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(sensitivity 0%), and the bedside CKiD detected 4 of 18
(sensitivity 22.2%). Therewere only 2 subjectswith a pre-HCT
nuclear GFR < 60 mL/min/1.73 m2. One was 4.5 months old
and would therefore be classiﬁed as having normal kidney
function based on age. The other subject had a nuclear GFR of
48.6 mL/min/1.73 m2 that would not have been detected by
either creatinine-based GFR formula (sensitivity 0%).
Secondary analysis: cystatin Ceand creatinine-estimated GFR
versus the nuclear GFR
The performance of CKiD GFR estimating equations
including cystatin C alone or in combination with creatinine
(Full CKiD) are shown in Table 3. Overall, equations including
creatinine and cystatin C performed better than equations
with creatinine alone. The Full CKiD formula had the best
mean bias at 3.6 (95% CI, 8.4 to 1.2) mL/min/1.73 m2,
which was not signiﬁcantly different from the nuclear GFR.
The CKiD cystatin Ceonly formula performed comparably
with the Full CKiD formula in terms of accuracy, although it
did slightly underestimate renal function (signiﬁcant mean
bias of8.6 mL/min/1.73m2). Both the Full CKiD and cystatin
Ceonly formulas had good accuracy, with 87.7% of values
falling within30% of the nuclear GFR and>40% falling with
10% of the nuclear GFR. However, they did not adequately
detect abnormal kidney function, with a sensitivity of 60.0%
for the cystatin Ceonly formula and a sensitivity of 40.0% for
the Full CKiD.
Performance of the estimating equations in children <2
and 18 years of age
The CKiD formulas were originally validated in children
2 years of age [16]. Because our cohort contained a subset of
subjects outside this age range, we separately examined the
performance of the GFR estimating equations in those
<2 years of age and18 years of age. In the primary analysis,
among the children <2 years of age (n ¼ 19), the original
Schwartz and bedside CKiD formulas again overestimated
the nuclear GFR with a signiﬁcant mean bias of 53.6 (95% CI,
22.0 to 85.3) and 24.9 (95% CI, 1.0 to 48.7) mL/min/1.73 m2,
respectively. In the secondary analysis (n ¼ 13), both the
CKiD cystatin Ceonly and Full CKiD formulas signiﬁcantly
underestimated the nuclear GFR with a signiﬁcant mean bias
of 20.6 (95% CI, 38.6 to 2.6) and 18.8 (95% CI, 33.4
to 4.2) mL/min/1.73 m2, respectively. No formula, creati-
nine or cystatin Cebased, identiﬁed the 2 young children
with abnormal kidney function.
In the primary analysis, among the subjects 18 years of
age (n ¼ 16), the pediatric-speciﬁc bedside CKiD performed
better than both the original Schwartz and the 2 adult-
speciﬁc formulas (MDRD and CKD-EPI creatinine). Specif-
ically, the bedside CKiD had a mean bias of 7.3 mL/min/
1.73 m2 (95% CI, 18.4 to 3.9) that was not signiﬁcantly
different from the nuclear GFR, an acceptable 30% accuracy
of 87.5%, and correctly identiﬁed 2 of 3 subjects (sensitivity of
66.7%) with a nuclear GFR <90 mL/min/1.73 m2. The original
Schwartz, MDRD, and CKD-EPI equations signiﬁcantly over-
estimated GFR with mean biases of 45.6 (95% CI, 30.8 to
60.5), 20.1 (95% CI, 8.1 to 32.0), and 21.3 (95% CI, 12.0 to 30.6)
mL/min/1.73 m2, respectively. In the secondary analysis
(n ¼ 13), the pediatric-speciﬁc cystatin Cebased formulas
performed better than the 2 adult formulas (CKD-EPI and
cystatin C). Speciﬁcally, the Full CKiD had a mean bias
of 4.6 mL/min/1.73 m2 (95% CI, 13.9 to 4.7) that was not
signiﬁcantly different from the nuclear GFR, whereas the
CKiD cystatin Ceonly formula again slightly underestimated
nuclear GFR with a mean bias of 11.4 mL/min/1.73 m2 (95%
CI, 21.1 to 1.7). Both formulas were accurate within 30%
of the nuclear GFR in all cases and correctly identiﬁed 1 of 2
subjects (sensitivity of 50.0%) with a nuclear GFR <90 mL/
min/1.73 m2. Both the CKD-EPI and cystatin C formulas
overestimated nuclear GFR, with mean biases of 14.9 and
19.4 mL/min/1.73m2, respectively, although they had a30%
accuracy of >75%.
Association between Pre-HCT Nuclear GFR and Post-HCT
Outcomes
Among the 95 subjects in our cohort, 50 (52.6%) devel-
oped AKI in the ﬁrst 100 days after HCT, as deﬁned by at least
1 serum creatinine value 2 times each subject’s baseline
value. Six subjects (6.3%) required dialysis, and 10 subjects
(10.5%) died within the ﬁrst 100 days after transplant. An
abnormal baseline nuclear GFR was not signiﬁcantly associ-
ated with an increased odds for developing post-HCT AKI
(odds ratio, .50; 95% CI, .18 to 1.44), needing dialysis (odds
ratio, 2.28; 95% CI, .38 to 13.55), or dying (odds ratio, 3.38;
95% CI, .84 to 13.56) in the ﬁrst 100 days after HCT.
DISCUSSION
We evaluated the performance of the most current GFR
estimating equations in a cohort of children and young adults
before HCT.We observed that althoughmost of the cohort had
normalkidney functionbeforeHCT, almost1 in5 subjectshada
nuclearGFR less thannormal for age before starting transplant.
Formulas relying on the serum creatinine (original Schwartz
formula and bedside CKiD) signiﬁcantly overestimated the
nuclear GFR and had a poor sensitivity for detecting abnormal
kidney function as measured by the nuclear GFR. Equations
including cystatin C performed better than those including
only creatinine, although they still failed to detect an abnormal
GFR in a signiﬁcant percentage of subjects. Finally, pediatric-
speciﬁc formulas performed better than adult-speciﬁc for-
mulas in the subset of subjects >18 years of age.
Our work expands on the few studies examining GFR
before HCT. Kletzel et al. [24] compared the original Schwartz
formula with a DTPA-measured GFR in 95 children. They
recommended using the Schwartz formula, even though it
overestimated the nuclear GFR by amean 14mL/min/1.73m2.
Qayed et al. [25] compared the original Schwartz and the
bedside CKiD formulas with a DTPA-measured GFR in 107
children >1 year of age. The Schwartz formula overestimated
nuclear GFR by 28 mL/min/1.73 m2 and the bedside CKiD
underestimated the GFR by 10mL/min/1.73m2; therefore, the
authors concluded that nuclear GFR testing should be
preferred for most patients before HCT. Hazar et al. [10]
compared cystatin C (Filler equation) and a nonstandard
creatinine formula with the DTPA-measured GFR in 34 chil-
dren. The cystatin Ceestimated GFR was similar to the nu-
clear GFR, whereas the creatinine-based GFR overestimated
kidney function. Finally, in 16 children undergoing autologous
HCT, we found that although cystatin Cebased equations
underestimated nuclear GFR, they outperformed the
creatinine-based bedside CKiD formula, which signiﬁcantly
overestimated GFR [6]. Notably, these studies consistently
demonstrated the limitations of creatinine-based methods to
accurately estimate GFR, with poor sensitivity and correlation
with nuclear GFR in this patient population.
To our knowledge, this is the largest study estimating
kidney function with cystatin C in the HCT population. Cys-
tatin C is a small housekeeping protein produced by all
nucleated cells in the body at a constant daily rate. It is freely
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ﬁltered by the glomerulus, independent of muscle mass,
minimally protein bound, and metabolized completely by
tubular cells after ﬁltration, making it an attractive endoge-
nous marker to estimate GFR [21]. Cystatin C has proven
superior to creatinine in detecting impaired GFR, especially
in speciﬁc patient populations [26]. For example, cystatin C
has demonstrated signiﬁcantly improved sensitivity to
identify renal impairment in children and adults receiving
chemotherapy for malignancy [27,28]. Similarly, our results
demonstrate that the CKiD cystatin Ceonly equation in
particular outperformed all creatinine-based equations in
identifying decreased GFR in children undergoing HCT.
Furthermore, both the CKiD cystatin Ceonly and Full CKiD
formulas offered improved accuracy compared with
creatinine-based equations. However, although our results
suggest that cystatin C may be a more useful marker than
creatinine for monitoring kidney function, at the current
time, cystatin Cebased methods do not offer sufﬁcient ac-
curacy to supplant formal nuclear GFR testing before HCT.
We estimated GFR with the most recent creatinine and
cystatin Cebased equations recommended by the 2012
Kidney Disease Improving Global Outcomes consensus
guidelines [13]. These equations have been validated in large
populations of children and adults, many of whom have
primary kidney disease [7,16,19]. However, as with any esti-
mating equation developed through statistical modeling, the
equations perform best in the original population and may
not be applicable to other groups of patients [5]. For example,
the CKiD equations were generated using data from children
with CKD and a median iohexol-measured GFR of 40 mL/
min/1.73 m2 [16], far lower than the average kidney function
in our cohort. The most recent CKD-EPI equation was
developed in a cohort of adults with a mean age of almost
50 years [19], possibly explaining why adult estimating
equations did not perform well in our young adult subjects.
It remains unknown if measuring GFR should become
routine practice before HCT. Although GFR estimation
methods using endogenous markers (creatinine and/or cys-
tatin C) are becoming more standardized and widely avail-
able [7], individual transplant centers may not have the
ability to measure GFR in all their patients. Cost should also
be a consideration, because we previously reported that
nuclear GFR testing is at least 10 times more expensive than
estimating GFR [6]. Importantly, more evidence is needed to
determine if screening for pre-HCT kidney dysfunction helps
to identify those at highest risk for poor outcomes. Although
we did not observe that a low pretransplant nuclear GFR
predicted later AKI, dialysis, or death in the ﬁrst 100 days, our
sample size was relatively small and likely underpowered to
detect signiﬁcant associations. Finally, it seems reasonable to
measure GFR in patients receiving certain conditioning
agents, such as platinum chemotherapy [2]. Accordingly, a
recent review [29] recommended that cyclophosphamide,
ﬂudarabine, and melphalan should also require dose ad-
justments in patients with kidney dysfunction. However, the
authors noted that more research in this area is needed
because the available literature, especially in children, pri-
marily includes small, retrospective reports [29].
Several limitations of our study deserve mention. First,
our cohort included a relatively small number of young
adults and children <2 years of age, so the ﬁndings may be
less applicable to these age groups. We used DTPA-measured
GFR as the gold standard, similar to previous reports in pa-
tients being evaluated for HCT [3,24,25]. However, unlike
EDTA (which is not available in the United States), DTPA may
not perfectly correlate with inulin clearance, perhaps due to
differences in the compound’s formulation [30]. As more
data become available on the use of iohexol, a nonradioac-
tive, safe to administer contrast agent currently used by
the CKiD research study, it may also become the marker of
choice in the clinical setting [7]. Because our study was a
cross-sectional analysis of an existing cohort, there was a
signiﬁcant time lag between some of the measurements,
potentially introducing bias if kidney functionwas not stable.
This was less of an issue in comparing creatinine-based GFR
with the nuclear GFR because the lag was minimal. However,
in the analyses including cystatin C, the lag was longer. We
tried to account for this by excluding subjects with “unsta-
ble” kidney function between measures. Finally, only 1 sub-
ject had a pre-HCT GFR <60 mL/min/1.73 m2, limiting our
ability to draw conclusions about which GFR method is
optimal to detect patients requiring dose adjustment to their
conditioning chemotherapy.
In conclusion, we observed that creatinine-based GFR
estimatingequationsperformedpoorly inchildrenbeforeHCT.
Cystatin Cebased equations performedbetter but still had low
sensitivity for detecting an abnormal GFR before transplant.
There are currently no clinical guidelines for themost effective
method to assess kidney function before HCT in children or
adults. We suggest that formal assessment of kidney function
should be considered in children and young adults needing an
accurate measure of GFR before HCT to properly dose certain
medications used for conditioning. We recommend that each
center develop a protocol for assessing kidney function before
HCT with input from the transplant team, nephrology, and
nuclear medicine. Only prospective studies designed to mea-
sure creatinine, cystatin C, and formal GFR testing at the same
time (or on the same sample) and correlating this information
with deﬁned clinical endpoints will deﬁnitively answer these
questions andhopefully improve kidney-related outcomes for
this high-risk population.
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